X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2023/04/04/2640441/0/en/Annals-of-Rheumatic-Diseases-Publishes-Results-from-Phase-2-Study-of-emapalumab-in-Patients-with-Secondary-HLH-Macrophage-Activation-Syndrome.html
https://www.prnewswire.com/news-releases/gamifant-emapalumab-recommended-for-approval-in-china-for-treatment-of-primary-haemophagocytic-lymphohistiocytosis-hlh-301490428.html
https://www.prnewswire.com/news-releases/emapalumab-submission-in-china-for-primary-hlh-301190141.html
https://www.sobi.com/en/press-releases/chmp-has-adopted-negative-opinion-emapalumab-europe-treatment-primary-hlh-1864708
https://endpts.com/sobi-bets-250m-cash-more-than-1b-in-milestones-for-rights-to-a-c3-therapy-being-pushed-through-5-pivotal-trials/
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020
http://www.pharmatimes.com/news/sobi_to_refile_gamifant_following_chmp_rejection_1345560
https://www.raps.org/news-and-articles/news-articles/2020/7/ema-thumbs-up-for-11-down-for-2-new-medicines
https://endpts.com/sobis-high-priority-rare-disease-drug-runs-into-a-wall-at-ema/
https://www.prnewswire.com/news-releases/results-from-pivotal-phase-23-study-of-emapalumab-in-patients-with-primary-hlh-published-in-new-england-journal-of-medicine-301054583.html
https://in.reuters.com/article/us-sobi-aquisition/sobi-buys-rare-disease-drug-emapalumab-zooms-in-on-hematology-and-immunology-idINKCN1TD1MZ
https://www.fiercebiotech.com/biotech/sobi-to-buy-novimmune-r-d-assets-lay-off-90-staff
https://www.prnewswire.com/news-releases/sobi-acquires-emapalumab-and-related-assets-300866267.html
https://www.fiercepharma.com/pharma/sobi-armed-positive-data-for-gamifant-embarks-rare-disease-launch
https://endpts.com/sobis-50m-bet-on-a-rare-disease-drug-pays-off-with-a-quick-fda-nod/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761107
https://endpts.com/sobi-signs-450m-deal-for-rare-disease-drug-emapalumab-boosting-its-inflammation-i-o-pipeline/
Market Place
Share 
